MET and non-small cell lung carcinoma: In a phase I study of Teliso‐V monotherapy for patients with advanced NSCLC (NCT02099058), forty c‐Met–positive patients (33 nonsquamous, six squamous, one mixed histology) were included in the final analysis.193